Remember when AI couldn’t crack a tough math problem without hallucinating formulas? Those days could soon be over. Maybe they already are. We could already have experimental AI systems that surpass 90% accuracy on the graduate-level Google-Proof Q&A benchmark GPQA Diamond), a test of graduate‐level reasoning in biology, physics, and chemistry. For context, in-domain experts…
R&D Market Pulse: Biden blocks $14.1B US Steel-Nippon deal, tech stocks drop
The R&D World Index (RDWI) for the week ending January 3, 2025, closed at 3,862.49 for the 25 companies in the RDWI — down –0.72% (or -28.10 basis points). Five RDWI members gained value last week, led by AbbVie (+1.80%), while Roche Holdings AG rose the least (+0.31%). Meanwhile, twenty RDWI members dipped, ranging from…
How medtech often gets more innovation bang for its R&D buck than pharma
In 2023, Merck & Co. spent more than half of its revenue on R&D. Sure, the figure was inflated thanks to its $10.8 billion acquisition of Prometheus Biosciences, which it budgeted as an R&D cost. But Moderna spent even more as a percentage, $4.85 billion of its $6.85 billion revenue in revenue on R&D while…
Some pundits sound alarm on AI’s $1 trillion gamble
A trillion-dollar question hangs over the booming field of artificial intelligence: will the massive investment pay off? Jim Covello, the head of global equity research at Goldman Sachs, sounds a note of caution. “AI technology is exceptionally expensive,” he warns, and to earn back the projected trillion-dollar cost of development and infrastructure, “the technology must…